CDRD, Canada’s national Centre for Drug Research and Development, is a global bridge that translates discoveries into innovative therapeutic products & improved health outcomes. In collaboration with our partners, we identify & advance promising discoveries & transform them into validated investments – all while uniquely training the next generation of highly-qualified personnel to drive the development of the innovations of tomorrow.
Scroll down to find out how we do this...
Identify & Evaluate
We proactively identify and evaluate
therapeutically promising and commercially relevant early-stage technologies within academia and Canadian life sciences companies.
Validate & Incubate
We replicate data, and build interdisciplinary
teams of experts to define and execute critical
experiments that will maximize probability of future clinical success and attract capital.
Accelerate & Commercialize
We generate valuable data around a technology, build a compelling business case and
comprehensive intellectual property package, and secure the private sector investors / partners to take the technology to patients.
Merck & CDRD Announce Joint Investment in the Canadian Life Sciences Ecosystem / Merck et le CDRD annoncent un investissement conjoint dans l’écosystème des sciences de la vie au CanadaNovember 3, 2017
Merck & CDRD announced the establishment of a new $1.5M Merck-CDRD Innovation Fund. This fund will go directly towards the advancement of projects of high therapeutic potential carried out at CDRD in collaboration with academic researchers....Fall Greetings to CDRD Stakeholders – Automne Message...Read More
October 17, 2017
Thank you for your ongoing commitment to CDRD. Nous vous remercions de votre attachement indéfectible à la cause du CDRD....Top global translational science organizations to catalyze...Read MoreMerck & CDRD Announce Joint Investment in the Canadian...Read More
Top global translational science organizations to catalyze translational innovation through new initiative – Translation TogetherSeptember 25, 2017
Five of the world’s top translational science organizations representing the European Union, the United Kingdom, the United States, Canada, and Australia have joined forces under the new banner of Translation Together. This new collaboration will enable the leveraging of complementary scientific and operational strengths of member...CDRD Launches New Video Series Featuring Tomorrow’s...Read MoreFall Greetings to CDRD Stakeholders – Automne Message...Read More
September 24, 2017
A key part of CDRD’s Mission is training the next generation of highly-qualified personnel to drive the development of new innovations. Visit our YouTube Channel to meet some of the impressive young CDRD scientists poised to take on that role....Sepset Biosciences Initiates Multicenter Human Clinical...Read MoreTop global translational science organizations to catalyze...Read More
September 13, 2017
Vancouver, BC: Marking World Sepsis Day, Sepset Biosciences Inc., announces the commencement of a multi-country, multi-center human clinical study that will validate and refine Sepset’s proprietary gene signature to quickly and accurately identify patients with sepsis. A spin-out of The Centre for Drug Research and Development...LifeArc, Dstl & CDRD Collaborate to Identify...Read MoreCDRD Launches New Video Series Featuring Tomorrow’s...Read More
June 27, 2017
LifeArc, CDRD, and the Defence Science and Technology Laboratory (Dstl), announced a new collaboration to identify antibacterial drug targets....Aequus Pharmaceuticals & CDRD Announce Research...Read MoreSepset Biosciences Initiates Multicenter Human Clinical...Read More
Aequus Pharmaceuticals & CDRD Announce Research Collaboration to Improve Cannabinoid-based TherapeuticsJune 1, 2017
This initial project leverages CDRD’s expertise in pre-clinical development & target validation for new products, & demonstrates CDRD’s ongoing engagement with life sciences companies in the Canadian marketplace. Products advanced through the collaboration will be commercialized by Aequus....New Progressive MS Translational Research Project LaunchedRead MoreLifeArc, Dstl & CDRD Collaborate to Identify...Read More
May 31, 2017
The MS Society of Canada & CDRD are excited to collaborate again to support a translational research project that could lead to the development of disease-modifying therapies for people living with progressive MS....CDRD Welcomes Aboriginal Students from Rural Alberta &...Read MoreAequus Pharmaceuticals & CDRD Announce Research...Read More
May 16, 2017
CDRD staff welcomed 4 new Aboriginal students to our headquarters for an intensive week of science training and mentorship through the Verna J. Kirkness Science and Engineering Program....Health Science Leaders Join Forces to Accelerate...Read MoreNew Progressive MS Translational Research Project LaunchedRead More
Health Science Leaders Join Forces to Accelerate Development of Treatments for Neurological Diseases / Des chefs de file en sciences de la santé unissent leurs forces pour accélérer le développement de traitements pour les maladies neurologiquesMarch 16, 2017
Three leading players in Canada’s health sciences sector are joining forces in a unique multi-million dollar partnership to create a novel drug development platform that will help advance new therapeutics for some of the most debilitating conditions such as amyotrophic lateral sclerosis (ALS), also known as...CDRD Welcomes Aboriginal Students from Rural Alberta &...Read More
JDRF is pleased to announce that it will contribute funding to Canada’s Zucara Therapeutics Inc., a pre-clinical life sciences company advancing...Read the article
An experimental treatment for bladder cancer will move into an early phase clinical trial under an agreement between Cancer Research UK...Read the article
Outcomes with Impact
September 19, 2017
CDRD is committed to training the next generation of highly-qualified personnel to drive the development of innovations. Hear more about our unique Training Program and the opportunities it is creating from some of our young scientists…....Novel therapies advancedRead More
August 24, 2017
CDRD has advanced 58 potential novel drug therapies towards the clinic. Many more are in production....Commercial transactionsRead MoreTraining the Next GenerationRead More
August 11, 2017
CDRD has completed 14 commercial transactions including the merger of CDRD spin-off company, Kairos Therapeutics, with BC-based Zymeworks Inc. and creating one of Canada’s leading biotherapeutics companies....Spin-off CompaniesRead MoreNovel therapies advancedRead More
August 11, 2017
CDRD has successfully created 7 spin-off companies including Kairos Therapeutics, Sitka Biopharma, Zucara Therapeutics, Precision Nanosystems, Immcure Therapeutics, Mesentech and Sepset Biopharma....Commercial transactionsRead More
Working with CDRD
Academic discovery is the watering hole of innovation, but developing discoveries into new therapeutic products is a challenging process that requires complementary expertise, infrastructure and resources to that typically available to an investigator. That's where CDRD comes in.
Whether a company is looking to accelerate development of their lead program or strengthen their pipeline by pulling a secondary program off the back-burner, CDRD provides solutions for whatever scientific and/or commercial roadblocks are impeding progress towards the next corporate value-creation point.